TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects With Moderate to Severe Atopic Dermatitis (AD).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female aged 18 to 65 years and in good general health~* Moderate to severe AD for at least 6 months prior to Randomization~* History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable~* EASI score ≥ 16 at Screening and at Randomization~* vIGA AD score ≥ 3 at Screening and at Randomization~* AD involved BSA ≥ 10% at Screening and at Randomization~Key Exclusion Criteria:~* Any factors that in the Investigator's opinion would predispose the subject to develop an infection~* Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status~* Not able to tolerate SC drug administration~* Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ANB032 SC Dose 1 (Type: EXPERIMENTAL): This arm will receive treatment SC
- ANB032 SC Dose 2 (Type: EXPERIMENTAL): This arm will receive treatment SC
- ANB032 SC Dose 3 (Type: EXPERIMENTAL): This arm will receive treatment SC
- Placebo (Type: PLACEBO_COMPARATOR): This arm will receive Placebo SC

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Measuring the Effects of Continuous Dopaminergic Stimulation on Nocturnal Movements in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with idiopathic PD (defined by UK Brain Bank criteria)~* Patients who will start treatment with rotigotine~* Hoehn \& Yahr stage II - IV~* Subjective sleep problems most likely caused by nocturnal hypokinesia, based on clinical interview~Exclusion Criteria:~* Other significant causes for nocturnal motor symptoms which are not dopamine-responsive~* Previous surgery for PD~* Mini- mental state examination score \< 25~* Concurrent hallucination or psychosis~* History of skin hypersensitivity to adhesives or other transdermals

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- parkinson's disease, nocturnal hypokinesia, rotigotine (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have received T cell receptor therapy in an Adaptimmune clinical study~* Subjects who have provided informed consent prior to their study participation~Exclusion Criteria:~* Not applicable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Genetically engineered T Cell Receptor- treated (Type: None): Long term follow-up of subjects with solid or hematological malignancies who have received lentivirus-mediated genetically engineered T Cell Receptors in a previous trial

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Newly diagnosed high-risk Neuroblastoma defined as: a. INSS 2A/2B older then 365 days with MYCN amplified, unfavorable histology, and any ploidy. b. INSS Stage 3, older than 365 days with MYCN amplification and/or unfavorable histology. c. INSS Stage 4 or 4S, less than 365 days of age, with MYCN amplification d. INSS Stage 4, over 365, regardless of MYCN amplification or histology.~2. Pre-transplant modalities may include surgery, chemotherapy, or radiation therapy. Radiation must not include lung fields. Only patients in complete response (CR), or partial response (PR) at the primary site will be eligible.~3. Any recurrent neuroblastoma with at least a partial response to salvage therapy.~4. Lansky performance score greater than or equal to 50 for patients \</= 16 years of age, or Zubrod performance status score of 0-2 for patients \> 16 years of age.~5. No symptomatic pulmonary disease. forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and Carbon Monoxide Diffusing Capacity (DLCO) \>/= 50% of expected corrected for hemoglobin. If unable to perform pulmonary function test (most children \< 6 years of age), pulse oximetry \>/= 92% on room air.~6. Adequate cardiac function as demonstrated by left ventricular ejection fraction \>/= 50% by echocardiogram.~7. Adequate hepatic function as defined as serum glutamic-oxaloacetic transaminase, SGOT (AST) and serum glutamic-pyruvic transaminase, SGPT (ALT)\< 5 times upper limits of normal.~8. All patients and/or their parents or legal guardians must sign a written informed consent.~9. Females of childbearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization must have a negative urine pregnancy test within 30 days of registering. Patients will be informed of the risk of not using adequate contraception.~Exclusion Criteria:~1. Patient is pregnant or breast-feeding.~2. Active infection not controlled by antibiotics after seven days of therapy.~3. Brain metastases.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transplantation CD133+ cells (Type: EXPERIMENTAL): Stem Cell Transplantation of CD133+ cells using the ClinicMACS in combination with Carboplatin + Etoposide + Melphalan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cold Therapy for Pain Control Following Caesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* greater than 36 weeks gestation~* primary C/S with Epidural for labor problems or breech presentation~* Repeat C/S with spinal~Exclusion Criteria:~* less than 36.0 week gestations~* vertical skin incisions~* classical or vertical hysterotomy incisions~* failed vaginal births after C/S (VBAC)~* past history of drug or alcohol abuse~* positive drug screens unless medical prescribed drugs~* general anesthesia~* Caesarean Hysterectomy~* primary C/S with spinal anesthesia

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: 43 Years
- Healthy Volunteers: t

Study Arms:
- Repeat C/S Control (Type: NO_INTERVENTION): Repeat C/S done with spinal without Alkantis ice pack but with similar size dressings.
- Repeat C/S Treatment (Type: ACTIVE_COMPARATOR): Repeat C/S done with spinal with Alkantis ice pack.
- Primary C/S - Control (Type: NO_INTERVENTION): Primary C/S done with Epidural without Alkantis ice pack but with similar size dressings.
- Primary C/S Treatment (Type: ACTIVE_COMPARATOR): Primary C/S done with Epidural with Alkantis ice pack.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prognostic Value of CTC in HNSCC Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytopathologically proven head and neck squamous cell carcinoma Age ≥ 20 years. Measurable or evaluable disease according to Response Evaluation Criteria In Solid Tumors(RECIST) criteria.~Ability to sign informed consent.~Exclusion Criteria:~* Prior cancers within 5 years, except for non-melanoma skin cancers, and in situ cervical cancers.~Inability to comply with study and/or follow-up procedures.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Menopause Osteoporosis and Bone Intervention Using Lifestyle Exercise.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* postmenopausal; aged ≥50 years~Exclusion Criteria:~* Volunteers will be excluded from the study if they: are using any medicated that may affect bone turnover (e.g., corticosteroids, anticonvulsants, anticoagulants, calcitonin, bisphosphonates, raloxifene, denosumab and/or anabolic agents such as parathyroid hormone and growth hormone or steroids), including hormone replacement therapy and hormone-based contraception, within 6 months of starting the study; have or have had any bone, metabolic, kidney, liver, thyroid, gastro-intestinal or hormonal disorders or cancer, that may affect bone turnover; have a close family history of osteoporosis; have sustained a low trauma fragility fracture in the past 6 months; are a heavy smoking (\>20 cigarettes/day); if they are already undertaking bone-specific jumping exercises or equivalent exercises; if they have an existing knee, hip or back injury or have any medical condition that would prevent them from completing the exercise. Additional exclusions at baseline testing will include: a low BUA score, i.e., estimated T score of \<2.5; obesity as determined by body mass index of \>35 km/m2, to minimise risk of strain or injury associated with the exercise. Participants will also not be able to undertake the bone scan if they have any foot swelling, as this can make results difficult to interpret.

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Jumping exercise (Type: EXPERIMENTAL): 10 rest-inserted jumps performed three times per week
- Balance exercise (Type: SHAM_COMPARATOR): Single-leg balances for 60 seconds on each leg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~For inclusion in the study participants must fulfill the following criteria:~* Provision of written informed consent prior to any study-specific procedures.~* Female or male aged ≥18 years at time of consent.~* Diagnosed with T2DM.~* Treatment with one or more non-insulin antihyperglycaemic medication(s) for at least 6 months prior to enrolment~* Own/have access to a smart phone with internet access and have access to the internet via a tablet or personal computer at least once a day. At the HCP's discretion, a patient may be without access to their smart phone service, data connection, and internet access for a period of time that should be ≤2 consecutive weeks~* HbA1c levels ≥8.0% and ≤11.0% within the last 6 months. If more than 1 value is available during the 6-month time period, all values must be within this range~* Body mass index (BMI) ≥25 and ≤55 kg/m2 within the last 3 months~* Ability to communicate in English~* Judged by their HCP to have suitable hearing, vision, manual dexterity, ability to understand instructions, and ability to use and understand smart phone and internet applications~* Negative pregnancy test (urine or serum) for female patients of childbearing potential~Exclusion criteria:~Participants cannot enter the study if any of the following exclusion criteria are fulfilled:~* Pregnancy~* Insulin use at baseline~* Current use of a smart phone- or web portal-based tool to help with management of T2DM~* History of type I diabetes or ketoacidosis~* Currently taking a weight loss medication~* Involvement in the planning and/or conduct of the study (applies to both AZ staff and/or staff and affiliates at the study site)~* Previous enrolment in the present study~* Participation in a clinical study with an investigational product or a disease state management program during the last 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care + digital disease management cohort (Type: None): Participants will have access to the smart phone- and web portal-based digital disease management tool in addition to standard care.
- Standard of Care cohort (Type: None): Participants will have standard care with no access to the digital disease management tool.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Motor-Sparing Femoral Nerve Block Dose

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 75 years~* American Society of Anesthesiologists classification 1-3~* Body mass index between 20 and 35~Exclusion Criteria:~* Adults who are unable to give their own consent~* Pre-existing neuropathy (assessed by history and physical examination)~* Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets≤ 100, International Normalized Ratio≥ 1.4 or partial prothrombin time ≥ 50)~* Renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)~* Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)~* Allergy to LA~* Pregnancy~* Prior surgery in the inguinal region~* Chronic pain syndromes requiring opioid intake at home

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- same dose (Type: EXPERIMENTAL): patient is exposed to the same previously successful dose
- lower dose (Type: EXPERIMENTAL): patient is exposed to a lower concentration dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>= 18 years.~2. ≥1 set of blood cultures positive for MRSA~3. Able to be randomized within 72 hours of blood cultures being collected.~4. Likely to remain as inpatient for 7 days following randomization~Exclusion Criteria:~1. Previous type 1 hypersensitivity reaction to ß-lactams~2. Polymicrobial bacteraemia (not counting contaminants)~3. Previous participation in the trial~4. Known pregnancy~5. Current β-lactam antibiotic therapy which cannot be ceased or substituted~6. Participant's primary clinician unwilling to enrol patient~7. Moribund (expected to die in next 48 hours with or without treatment)~8. Treatment limitations which preclude the use of antibiotics Note that we are NOT planning to exclude participants with renal failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard therapy (Type: NO_INTERVENTION): Intravenous vancomycin dosed as per Australian Therapeutic Guidelines (loading dose of 25 mg/kg followed by maintenance dose of 15-20 mg/kg every 12 hours) with subsequent adjustment to maintain trough levels at 15-20 mg/dL OR Intravenous daptomycin 6-10 mg/kg per day, adjusted for renal function (details of renally adjusted dosing provided in full protocol).~The choice of daptomycin or vancomycin is clinician-determined and may be influenced by such factors as local practice, the vancomycin minimum inhibitory concentration (MIC) of the isolate and evidence emerging during the course of the study
- Standard therapy + Beta-Lactam (Type: EXPERIMENTAL): In addition to standard treatment an intravenous Beta-Lactam (β-lactam) will be added for the first 7 calendar days following randomisation (randomisation is day 1 - hence patients will receive 6-7 days of β-lactam). This β-lactam will be intravenous flucloxacillin 2g every 6 hours in Australia and intravenous cloxacillin 2g every 6 hours in Singapore. For those with a history of minor allergy to any penicillin (rash or unclear history, but not anaphylaxis or angiooedema), it will be intravenous cefazolin 2g every 8 hours. For haemodialysis patients, it will usually be cefazolin 2g three times per week post dialysis, however clinicians are also free to choose intermittent (flu)cloxacillin, dosed as for glomerular filtration rate (GFR ) \<10, if they desire.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: SJM Brady MRI Post Approval Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subject is able to provide informed consent for study participation (legally authorized representative is NOT acceptable).~2. Subject is at least 18 years of age or of legal age to give informed consent specific to state and national law.~3. Subject meets at least one of the following criteria:~   1. Is an Accent MRI IDE study subject who is being rolled over into the SJM Brady MRI PAS and still has at least one Tendril MRI™ lead implanted with a SJM Brady MRI pacemaker such as the Accent MRI or similar model.~  2. Is a subject who has been implanted with at least one Tendril MRI lead and a SJM Brady MRI pacemaker such as the Accent MRI or similar model, but is not part of the Accent MRI IDE study and will be enrolled within 30 days after implant.~  3. Is a subject who will be implanted with at least one Tendril MRI lead and a SJM Brady MRI pacemaker such as the Accent MRI or similar model and will be consented either at or within 30 days before implant.~4. Subject is willing and able to comply with the prescribed follow-up tests and schedule of evaluations including MRI scan procedures.~Exclusion Criteria:~1. Subject has been enrolled or intends to participate in a clinical drug and/or device study with an active treatment arm or that has any procedures, which could confound the results of this trial.~2. Subject is not expected to be able to complete the study follow up schedule or duration due to any health condition such as has malignancy, is deemed a candidate for transplant or Ventricular Assist Device, or in hospice care.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥16 years old (\>18 years of age in the United States)~* Admitted to hospital with confirmed COVID-19 respiratory illness~* Receiving supplemental oxygen~* 500 mL of ABO compatible convalescent plasma is available~Exclusion Criteria:~* Onset of respiratory symptoms \>12 days prior to randomization~* Intubated or plan in place for intubation~* Plasma is contraindicated (e.g. history of anaphylaxis from transfusion)~* Decision in place for no active treatment

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent plasma (Type: EXPERIMENTAL): \~500 mL ABO compatible convalescent apheresis plasma
- Standard of care (Type: NO_INTERVENTION): Treated as per institutional standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy